Background: We recently identified a human B-cell population that is naturally autoreactive and tolerized by functional anergy (BND cells).

Objective: We sought to identify the molecular mechanism of how anergic autoreactive BND cells escape functional anergy and whether this process is altered in patients with lupus.

Methods: Isolated peripheral blood naive and BND cells were cultured with various stimuli, and their activation status was determined by using an intracellular Ca(2+) mobilization assay. Lyn kinase and Syk activities were assessed by using phospho-flow analysis. CD45 phosphatase activity was determined by using a novel flow-based assay, which takes advantage of the fluorogenic properties of phosphorylated coumaryl amino propionic acid, an analog of phosphotyrosine, which can be incorporated into peptides. Real-time quantitative PCR was used to quantitate LYN, SYK, and CD45 mRNA.

Results: T-helper signals reversed the state of anergy, allowing BND cells to fully respond to antigenic stimulation by restoring signaling through the B-cell receptor (BCR). The mechanism was dependent on increased activity of the tyrosine phosphatase CD45 and CD45-dependent activation of Lyn and Syk. CD45 phosphatase activity was increased by T-cell help both in BND and naive B cells. Furthermore, we found that BND cells obtained from patients with systemic lupus erythematosus exhibited increased CD45 activity and BCR-signaling capacity, thus being less tolerized than BND cells from healthy control subjects.

Conclusion: Our findings suggest that CD45 is a key regulator of BCR-signaling thresholds mediated by T-cell help. This raises the possibility that BND cells could represent precursors of autoantibody-secreting plasma cells and suggests a role for these autoreactive B cells in contributing to autoimmunity if not properly controlled.

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.jaci.2016.01.035DOI Listing

Publication Analysis

Top Keywords

bnd cells
24
cd45 phosphatase
12
phosphatase activity
12
t-helper signals
8
b-cell receptor
8
cells
8
functional anergy
8
bnd
8
lyn syk
8
syk cd45
8

Similar Publications

Elevated frequencies of activated memory B cells in multiple sclerosis are reset to healthy control levels after B cell depletion with Ocrelizumab.

J Neuroimmunol

December 2024

Versiti Blood Research Institute, Milwaukee, WI, USA; Department of Microbiology and Immunology, Medical College of Wisconsin, Milwaukee, WI, USA. Electronic address:

In multiple sclerosis (MS) the B cell depleting drug ocrelizumab has shown high efficacy in reducing inflammatory activity. Its mechanism of action is unclear due to B cell subset complexity and unknown roles in pathogenesis. Here, we comprehensively phenotyped and quantitated peripheral blood B cell subsets before and after ocrelizumab infusion to gain insight into the fate of B cell subsets with pathogenic potential.

View Article and Find Full Text PDF
Article Synopsis
  • The study aimed to determine how different durations of intraoperative radiofrequency ablation affect the health and characteristics of bursal cells collected during rotator cuff surgery in patients.
  • Six healthy patients participated, and bursal tissue was subjected to varying levels of ablation to assess cell viability, growth potential, and phenotypes.
  • Findings showed that longer ablation times led to reduced viability of the cells, but the overall characteristics of the cells remained consistent across different treatment groups, indicating that while ablation affects cell survival, it does not significantly alter cell properties.
View Article and Find Full Text PDF

Purpose: Circulating tumor cell (CTC)-based (HER2) assay is a laboratory test developed by Epic Sciences using single-cell genomics to detect (HER2) amplification in CTCs found in the peripheral blood of metastatic breast cancer (MBC) patients.

Patients And Methods: Peripheral blood was collected in Streck tubes and centrifugation was used to remove plasma and red blood cells. The remaining nucleated cells were deposited on glass slides, immunofluorescent-stained with proprietary antibodies, scanned by a high-definition digital scanner, and analyzed by a proprietary algorithm.

View Article and Find Full Text PDF

Deep Immunoprofiling of Large-Scale Tuberculosis Dataset at Single Cell Resolution Reveals a CD81 γδ T Cell Population Associated with Latency.

Cells

September 2024

Central Laboratory of Advanced Diagnosis and Biomedical Research (CLADIBIOR), Azienda Ospedaliera Universitaria Policlinico (A.O.U.P.) Paolo Giaccone, University of Palermo, 90127 Palermo, Italy.

Tuberculosis (TB) remains one of the leading causes of death among infectious diseases, with 10.6 million new cases and 1.3 million deaths reported in 2022, according to the most recent WHO report.

View Article and Find Full Text PDF

Efficient α and β radionuclide therapy targeting fibroblast activation protein-α in an aggressive preclinical mouse tumour model.

Eur J Nucl Med Mol Imaging

January 2025

Vrije Universiteit Brussel, Department of Biomedical Sciences, Translational Oncology Research Center, Laboratory for Molecular and Cellular Therapy, Laarbeeklaan 103. Building E, Brussels, 1090, Belgium.

Article Synopsis
  • - The study investigates the effectiveness of targeted radionuclide therapy (TRT) using FAP-targeted sdAbs (4AH29) in a lung cancer mouse model, examining both the treatment's biodistribution and its therapeutic outcomes when combined with PD-L1 immune checkpoint blockade.
  • - Results indicated significant tumor uptake of the therapies, with improved survival rates in treated mice compared to those receiving only the vehicle solution, and increased PD-L1 expression in tumors after treatment.
  • - The combination of high-dose [Ac]Ac-DOTA-4AH29 TRT with PD-L1 ICB showed enhanced therapeutic synergy, suggesting a promising approach for treating aggressive tumors.
View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!